Rowan University and Sentrimed®, a clinical-stage biopharmaceutical firm centered on growing safer, orally dosed oncology therapies, at the moment introduced outcomes from a National Cancer Institute (NCI) funded clinical trial evaluating MASL® in sufferers with oral squamous cell carcinoma (OSCC). The Company’s lead product candidate, MASL, is a novel lectin-based therapeutic licensed from Rowan University. Results from this first-in-human Phase 1 trial, led by Dr. Gary Goldberg on the Rowan-Virtua School of Osteopathic Medicine and Dr. Mahnaz Fatahzadeh from the Rutgers School of Dental Medicine, have been not too long ago revealed within the Journal of Cancer Research and Clinical Oncology and demonstrated the potential of MASL to handle essential unmet wants within the treatment of oral cancer.
MASL is a first-in-class, orally administered therapeutic that targets podoplanin (PDPN), an oncogenic transmembrane glycoprotein receptor that’s expressed on malignant cells in additional than 75% of oral cancer sufferers. PDPN performs a key position in selling tumor cell proliferation, migration, immune evasion, and resistance to remedy. By focusing on PDPN, MASL might disrupt key oncogenic signaling pathways that drive cancer development and mortality.
“Results from this research recommend that MASL will be developed to assist deal with sufferers with OSCC lesions,” mentioned Dr. Gary Goldberg, who has carried out pioneering analysis on intercellular communication and its position in cancer development, and is a Founder and Chief Scientific Officer at Sentrimed. “The single oral dose of MASL used on this research prompted no hostile reactions or uncomfortable side effects in any sufferers. In addition, MASL appeared to stimulate an antitumor immune response in a single out of three sufferers examined inside 24 hours after dosing. This first-in-human research marks a important milestone within the growth of MASL and we look ahead to increasing its investigation in bigger clinical trials.”
Ex-vivo research utilizing patient-derived tumor cells from this Phase 1 trial discovered that MASL constantly inhibited oral cancer cell viability and motility in tradition. Moreover, research with these cells additionally point out that antibodies can goal PDPN to selectively destroy human oral cancer cells utilizing near-infrared photoimmunotherapy (NIR-PIT). This analysis was supported by Rowan University, Rutgers University, the NIH, Sentrimed, and collaborators from the New Jersey Medical School, NCI, and Tohoku University.